IL302329A - A method for treating cancers using alkyne-modified quinsoline derivatives - Google Patents

A method for treating cancers using alkyne-modified quinsoline derivatives

Info

Publication number
IL302329A
IL302329A IL302329A IL30232923A IL302329A IL 302329 A IL302329 A IL 302329A IL 302329 A IL302329 A IL 302329A IL 30232923 A IL30232923 A IL 30232923A IL 302329 A IL302329 A IL 302329A
Authority
IL
Israel
Prior art keywords
compound
egfr
cancer
pharmaceutically acceptable
administered
Prior art date
Application number
IL302329A
Other languages
English (en)
Hebrew (he)
Original Assignee
Black Diamond Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Black Diamond Therapeutics Inc filed Critical Black Diamond Therapeutics Inc
Publication of IL302329A publication Critical patent/IL302329A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL302329A 2020-11-02 2021-11-02 A method for treating cancers using alkyne-modified quinsoline derivatives IL302329A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063108645P 2020-11-02 2020-11-02
US202163166045P 2021-03-25 2021-03-25
US202163190067P 2021-05-18 2021-05-18
US202163218717P 2021-07-06 2021-07-06
US202163237782P 2021-08-27 2021-08-27
US202163244540P 2021-09-15 2021-09-15
PCT/US2021/057724 WO2022094464A1 (en) 2020-11-02 2021-11-02 Method of treating cancers with alkyne substituted quinazoline derivatives

Publications (1)

Publication Number Publication Date
IL302329A true IL302329A (en) 2023-06-01

Family

ID=78819639

Family Applications (1)

Application Number Title Priority Date Filing Date
IL302329A IL302329A (en) 2020-11-02 2021-11-02 A method for treating cancers using alkyne-modified quinsoline derivatives

Country Status (10)

Country Link
US (1) US20240075042A1 (cg-RX-API-DMAC7.html)
EP (1) EP4236954A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023548055A (cg-RX-API-DMAC7.html)
KR (1) KR20230093429A (cg-RX-API-DMAC7.html)
AU (1) AU2021368798A1 (cg-RX-API-DMAC7.html)
CA (1) CA3195473A1 (cg-RX-API-DMAC7.html)
IL (1) IL302329A (cg-RX-API-DMAC7.html)
MX (1) MX2023004998A (cg-RX-API-DMAC7.html)
TW (1) TWI910256B (cg-RX-API-DMAC7.html)
WO (1) WO2022094464A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020328598B2 (en) 2019-08-15 2026-07-02 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds
WO2023049168A1 (en) * 2021-09-21 2023-03-30 Black Diamond Therapeutics, Inc. Polymorphs as erbb inhibitors
WO2025038731A1 (en) * 2023-08-15 2025-02-20 Black Diamond Therapeutics, Inc. Method of treating cancers with alkyne substituted quinazoline derivatives
WO2025128831A1 (en) * 2023-12-13 2025-06-19 Black Diamond Therapeutics, Inc. Combinations comprising alkyne substituted quinazoline derivatives and their use in the treatment of cancer
WO2025137421A1 (en) * 2023-12-21 2025-06-26 Black Diamond Therapeutics, Inc. Compositions comprising alkyne substituted quinazoline derivatives and related uses
WO2026064728A1 (en) * 2024-09-23 2026-03-26 Black Diamond Therapeutics, Inc. Method of treating cancers with alkyne substituted quinazoline derivatives

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2680850B1 (en) * 2011-03-04 2018-05-23 Newgen Therapeutics, Inc. Alkyne substituted quinazoline compound and methods of use
HRP20230305T1 (hr) * 2014-12-24 2023-05-26 Principia Biopharma Inc. Pripravci za ileo-jejunalnu dostavu lijeka
WO2020068867A1 (en) * 2018-09-25 2020-04-02 Black Diamond Therapeutics, Inc. Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use
AU2020328598B2 (en) * 2019-08-15 2026-07-02 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds

Also Published As

Publication number Publication date
AU2021368798A9 (en) 2023-07-06
JP2023548055A (ja) 2023-11-15
WO2022094464A1 (en) 2022-05-05
KR20230093429A (ko) 2023-06-27
MX2023004998A (es) 2023-05-12
US20240075042A1 (en) 2024-03-07
TWI910256B (zh) 2026-01-01
TW202235083A (zh) 2022-09-16
CA3195473A1 (en) 2022-05-05
AU2021368798A1 (en) 2023-05-18
EP4236954A1 (en) 2023-09-06

Similar Documents

Publication Publication Date Title
US20240075042A1 (en) Method of treating cancers with alkyne substituted quinazoline derivatives
KR102857219B1 (ko) 암의 치료 또는 예방용 의약
JP5778735B2 (ja) Egfr依存性疾患またはegfrファミリーメンバーを標的とする薬剤に対して耐性を獲得した疾患を治療するためのピリミジン誘導体の使用
TWI920018B (zh) 抗her3抗體-藥物結合物用於治療her3突變癌之醫藥的用途
TW202128174A (zh) 失調之纖維母細胞生長因子受體訊息傳遞的癌症之標靶性治療
EP3226869A1 (en) Kinase inhibitor prodrug for the treatment of cancer
US20220041613A1 (en) Tyrosine kinase inhibitor compositions, methods of making and methods of use
JP2026048890A (ja) 抗体-薬物複合物及びcdk9阻害剤の組み合わせ
KR20240099193A (ko) Erbb 억제제로서의 다형체
WO2025038731A1 (en) Method of treating cancers with alkyne substituted quinazoline derivatives
CN116710096A (zh) 用炔取代的喹唑啉衍生物治疗癌症的方法
US20230321087A1 (en) Fgfr inhibitor combination therapies
AU2021359826A1 (en) Dosing regimens for cyclin‑dependent kinase 7 (cdk7) inhibitors
EP4534085A1 (en) Compounds for use in methods of treating cancer
WO2026064728A1 (en) Method of treating cancers with alkyne substituted quinazoline derivatives
CN118791477A (zh) Aak1抑制剂及其用途
TW201217341A (en) Receptor-type kinase modulator and methods of treating polycystic kidney disease